在新生儿重症监护病房使用低剂量多巴胺
Mallory A Prideaux1, Ronnie Guillet1
1Division of Neonatology, Golisano Children's Hospital, University of Rochester, Rochester, NY.
NeoReviews
|March 31, 2024
概括
低剂量多巴胺在新生儿中广泛用于预防急性损伤 (AKI),但证据不支持其有效性. 尽管已知有不良影响,但这种做法仍在继续,特别是在早产儿身上.
科学领域:
- 新生儿医学 新生儿医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 多巴胺几十年来一直用于治疗低血压,理论上可以预防急性损伤 (AKI).
- 脏多巴胺受体的激活会增加尿液的产量.
- 然而,缺乏证据支持多巴胺在减少AKI发病率,透析需求或死亡率方面的有效性.
研究的目的:
- 审查当前关于新生儿使用低剂量多巴胺的医学知识.
- 评估多巴胺在预防或治疗新生儿AKI中的作用的证据.
- 讨论多巴胺的不良影响,特别是早产婴儿.
主要方法:
- 对新生儿群体中多巴胺使用研究的文献综述.
- 关于多巴胺对AKI,透析和死亡率的影响的证据分析.
- 检查在新生儿中报告的多巴胺不良影响.
主要成果:
- 没有证据表明低剂量的多巴胺可以减少AKI发生率,透析需要或死亡.
- 多巴胺的使用与显著的不良影响有关,特别是在早产婴儿.
- 尽管有有限的证据和已知的风险,低剂量的多巴胺仍然用于新生儿AKI.
结论:
- 目前的证据不支持使用低剂量多巴胺来预防或治疗新生儿的AKI.
- 副作用,特别是在脆弱的早产婴儿中,需要谨慎.
- 需要进一步的研究和对当前临床实践的重新评估.
更多相关视频
19:15Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
85.9K
05:45Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures
Published on: November 2, 2015
7.3K
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
313
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
313